Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00002304 · ClinicalTrials.gov registry record · NA

A Comparison of Fluconazole and Ketoconazole in the Treatment of Fungal Infections of the Throat in Patients With Weakened Immune Systems

A NA study of HIV Infections and Candidiasis, Esophageal, sponsored by Pfizer.

Completed
Registry status
NA
Development phase
20
Study locations

NCT00002304: Completed NA study of HIV Infections and Candidiasis, Esophageal, sponsored by Pfizer.

NCT00002304 is a NA study of HIV Infections and Candidiasis, Esophageal that has completed, run by Pfizer. The trial reports 20 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00002304, a NA study of HIV Infections and Candidiasis, Esophageal, has completed, sponsored by Pfizer.

COMPLETED
Registry status
NA
Development phase
20
Study locations

Study Summary

To compare the safety, tolerance, and effectiveness of fluconazole and ketoconazole in the treatment of candidal esophagitis in immunocompromised patients.

Interventions

  • DRUG Fluconazole
  • DRUG Ketoconazole

Study Locations (20)

Georgia

  • Georgia Baptist Med Ctr - Atlanta
  • DeKalb Gen Hosp - Decatur
  • Gwinnett Med Ctr - Lawrenceville
  • Atlanta Hosp - Riverdale
  • Clayton Gen Hosp - Riverdale
  • Dr Winkler Weinberg - Roswell

Florida

  • Regional Oncology Ctr - Daytona Beach
  • Ctr for Special Immunology - Fort Lauderdale
  • Mem Hosp Hollywood - Hollywood
  • Med Ctr Clinic - Pensacola
  • St Petersburg Med Clinics - St. Petersburg

California

  • Los Angeles County - USC Med Ctr - Los Angeles
  • Eisenhower Med Ctr - Rancho Mirage
  • ViRx Inc - San Francisco
  • UCSF Hosp - San Francisco

Massachusetts

  • Univ Hosp - Boston
  • Baystate Med Ctr of Springfield - Springfield

Arizona

  • Good Samaritan Med Ctr - Phoenix

Arkansas

  • Arkansas Children's Hosp - Little Rock

District of Columbia

  • George Washington Univ Med Ctr - Washington D.C.

Trial Details

FieldValue
Phase NA
Pfizer

1,845 total trials

What the finished NCT00002304 record still lists

NCT00002304 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.

The record links to 2 conditions, with HIV Infections appearing as the primary indexed condition, and to 2 interventions - of which Fluconazole is the first listed.

NCT00002304 names 20 study sites across 7 states, led by Georgia, Florida, California.

Frequently Asked Questions

What is clinical trial NCT00002304 about?

NCT00002304 is a clinical study titled "A Comparison of Fluconazole and Ketoconazole in the Treatment of Fungal Infections of the Throat in Patients With Weakened Immune Systems". To compare the safety, tolerance, and effectiveness of fluconazole and ketoconazole in the treatment of candidal esophagitis in immunocompromised patients.

What is the current status of trial NCT00002304?

This trial is currently completed. It is a NA study.

What conditions does trial NCT00002304 study?

This clinical trial studies the following conditions: HIV Infections, Candidiasis, Esophageal.

What interventions are being tested in trial NCT00002304?

The interventions under investigation include: Fluconazole (DRUG), Ketoconazole (DRUG).

Who is sponsoring clinical trial NCT00002304?

This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00002304 being conducted?

This trial has 20 study locations across Arizona, Arkansas, California, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Source: ClinicalTrials.gov NCT00002304, the US trial registry maintained by the National Library of Medicine. NCT00002304 (unsized enrollment · wide site footprint · completed) retrieved and formatted by PlainTrial, see methodology.